Lanois-Nouri A, Pantel L, Fu J, Houard J, Ogier JC, Polikanov YS, Racine E, Wang H, Gaudriault S, Givaudan A, Gualtieri M
The Odilorhabdin Antibiotic Biosynthetic Cluster and Acetyltransferase Self-Resistance Locus Are Niche and Species Specific [https://journals.asm.org/doi/10.1128/mbio.02826-21]
mBio (2022)
Subscribe to our newsfeed
Nosopharm is open to synergistic collaborations for the development of its pipeline and the progress of its promising drug discovery programs.
Our goal is to explore, with an industrial partner, the drug discovery potential of Photorhabdus and Xenorhabdus bacteria for human and animal health in any therapeutic indication. Our innovative anti-infective drug discovery platform is based on the exploitation of these two antimicrobial-producing bacteria; Nosopharm is the only biotech company to explore these. Nosopharm is also interested in gaining access to new strains of Photorhabdus and Xenorhabdus or related bacteria, in compliance with the Nagoya Protocol.
To explore partnering opportunities with Nosopharm, please contact us.
Nosopharm is an innovative biotechnology company specialized in exploring the microbial biodiversity of the genera Photorhabdus and Xenorhabdus to develop new drugs infectious diseases.
